Regeneron Pharmaceuticals (NASDAQ:REGN) PT Lowered to $1,150.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target trimmed by JPMorgan Chase & Co. from $1,200.00 to $1,150.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on REGN. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Piper Sandler lifted their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,101.00.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $933.02 on Thursday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average price is $1,088.44 and its two-hundred day moving average price is $1,041.27. The company has a market cap of $102.81 billion, a PE ratio of 27.56, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period in the previous year, the firm earned $8.79 EPS. The firm’s revenue was up 12.3% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post 37.66 EPS for the current year.

Insiders Place Their Bets

In related news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of REGN. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the period. Capital International Investors grew its position in shares of Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after acquiring an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the period. TD Asset Management Inc increased its position in Regeneron Pharmaceuticals by 162.9% in the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock worth $259,402,000 after buying an additional 166,998 shares during the last quarter. Finally, Swedbank AB bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $129,257,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.